22211 WEST INTERSTATE-10, SAN ANTONIO, TX
Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
Announces Grant of Hong Kong Patent for CyPath® Lung Noninvasive Lung Cancer Diagnostic
Q2
FY 2025
Q3
Q1
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
Definitive Proxy Statement
PRER14A
PRE 14A
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement